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To the Editor: 
We thank Zeuzem et al for their response to our recently published findings (1, 2). Their 
data provide a valuable addition to reports describing virological outcomes for patients 
infected with “rare” subtypes who have received sofosbuvir (SOF)-based therapy but have 
not been well represented in previous large-scale clinical trials. We agree with the authors 
that assessing treatment outcome in cohorts infected with poorly characterized or 
uncharacterized subtypes would ideally be determined from patients who have achieved 
both SVR and treatment relapse. However, well-defined cohorts do not exist in most low- 
and middle-income countries (LMICs) where such subtypes are typically found, and 
consequently the necessary evidence base has been lacking. 
We wish to comment further on the implications for treatment of patients in LMICs as part 
of the WHO global elimination plan. Recently, we published a study illustrating the lack of 
HCV sequence data in LMICs, particularly those in Africa as well as South and Central 
America (3). We agree that a SVR rate of 100% in 8 gt4r-infected patients treated with 
SOF/VEL±VOX is reassuring. However, the additional finding of SOF/LDV treatment failure 
in 2/4 patients with gt4r in Zeuzem et al’s larger analysis (1) is concerning although the 
authors did not give details of the disease status of these patients. In our study, all EAP 
patients had cirrhosis, which may well have influenced response to therapy. The apparent 
lower response of gt4r to SOF/LDV is worth highlighting for countries planning to use 
generic versions of these DAAs as treatment for gt4 infection where a significant proportion 
of patients are possibly infected with the gt4r subtype. Although gt4r is uncommon in 
Europe and the USA, it is not a rare genotype in Central African countries including the 
Democratic Republic of the Congo, the Republic of Congo, the Central African Republic, 
Burundi, and Gabon. It will be important for these countries to consider the potential 
advantage of using SOF/VEL-based treatment versus SOF/LDV to achieve high rates of 
HCV clearance.   
Finally, the large dataset provided by Zeuzem et al substantially increases the available 
data for DAA target genes in subtypes that are rare in high income countries (HICs). 
However, there remains a question as to whether the full extent of RAS polymorphisms in 
such subtypes should be considered as fully documented. Regarding gt1l, also associated 
with lower SVR rates in our study, we combined the sequence data for gt1l isolates across 
the HCV NS5A coding region between residues 24-32 where RAS typically occur from 
Zeuzem et al, our publication (Filipe et al) and available Genbank sequences. Our analysis 
shows that methionine is dominant at positions 28 and 31 (11/12 sequences). However, 
position 30 is polymorphic in gt1l (Q, n=7; R, n=5). In the common gt1 subtypes, gt1a 
and gt1b, position 30 does not show such variability; for gt1a, Q is encoded in 96% of 
sequences (4801/4983) and for gt1b, R is encoded in 92% of sequences (4328/4705) 
(McLauchlan, unpublished). The motif consisting of M28R30M31 is found not only in gt1l but 
also gt4r. The gt1l-infected patients reported by Zeuzem et al who had this motif received 
VEL and not LDV, which was the prescribed NS5A inhibitor in our EAP cohort. We note that 
one of the gt4r-infected patients in the Zeuzem et al study with the M28R30M31 motif did 
receive LDV and relapse occurred, the second patient who received LDV had a V28R30M31 
motif. All other gt4r-infected patients who achieved SVR received SOF/VEL±VOX. In the 
absence of relevant in vitro subgenomic replicons to test gt1l, we agree with Zeuzem et al 
that patients receiving SOF-based regimens for gt4r should be treated with VEL but this 
recommendation could be extended to geographic regions where gt1l may circulate to 
mitigate against possible resistance with strains containing the V/M28R30M31 motif.  
In summary, the available, modest data suggest that NS5A polymorphisms, which may 
impact treatment response are common in HCV strains from certain African genotypes. 
The impact of these polymorphisms appears to be minimal in patients receiving SOF/VEL-
based regimens but there are concerns about the efficacy of LDV in these isolates. Further 
studies examining the effectiveness of current therapies in larger numbers of patients will 
be required to identify the optimum regimen for these potentially resistant subtypes. 
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